Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Presse Medicale (Paris, France : 1983)
|
July 20, 2005
[Selective cyclooxygenase-2 inhibitors. A population-based analysis of use in France over a three-year period and comparison with randomised clinical trials]
Guy-Robert Auleley, Jean Deligne, Catherine Hantson, et al.
Plos One
|
April 6, 2012
Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs
Cécile Konrat, Isabelle Boutron, Ludovic Trinquart, et al.
Journal of Clinical Epidemiology
|
June 16, 2004
The methods for handling missing data in clinical trials influence sample size requirements
Guy-Robert Auleley, Bruno Giraudeau, Gabriel Baron, et al.
Arthritis and Rheumatism
|
January 11, 2003
Evaluation of the smallest detectable difference in outcome or process variables in ankylosing spondylitis
Guy-Robert Auleley, Karima Benbouazza, Anneke Spoorenberg, et al.
British Journal of Clinical Pharmacology
|
January 20, 2012
Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers
Marie Tournier, Bernard Bégaud, Audrey Cougnard, et al.
European Journal of Clinical Pharmacology
|
November 21, 2007
Prevalence and patterns of methylphenidate use in French children and adolescents
Anne-Laure Knellwolf, Jean Deligne, Flavia Chiarotti, et al.
Inflammatory Bowel Diseases
|
November 11, 2009
Fine-scale geographic variations of inflammatory bowel disease in France: correlation with socioeconomic and house equipment variables
Virginie Nerich, Elisabeth Monnet, Alain Weill, et al.
Inflammatory Bowel Diseases
|
March 15, 2006
Geographical variations of inflammatory bowel disease in France: a study based on national health insurance data
Virginie Nerich, Elisabeth Monnet, Arnaud Etienne, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Presse Medicale (Paris, France : 1983)
|
July 20, 2005
[Selective cyclooxygenase-2 inhibitors. A population-based analysis of use in France over a three-year period and comparison with randomised clinical trials]
Guy-Robert Auleley, Jean Deligne, Catherine Hantson, et al.
Plos One
|
April 6, 2012
Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs
Cécile Konrat, Isabelle Boutron, Ludovic Trinquart, et al.
Journal of Clinical Epidemiology
|
June 16, 2004
The methods for handling missing data in clinical trials influence sample size requirements
Guy-Robert Auleley, Bruno Giraudeau, Gabriel Baron, et al.
Arthritis and Rheumatism
|
January 11, 2003
Evaluation of the smallest detectable difference in outcome or process variables in ankylosing spondylitis
Guy-Robert Auleley, Karima Benbouazza, Anneke Spoorenberg, et al.
British Journal of Clinical Pharmacology
|
January 20, 2012
Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers
Marie Tournier, Bernard Bégaud, Audrey Cougnard, et al.
European Journal of Clinical Pharmacology
|
November 21, 2007
Prevalence and patterns of methylphenidate use in French children and adolescents
Anne-Laure Knellwolf, Jean Deligne, Flavia Chiarotti, et al.
Inflammatory Bowel Diseases
|
November 11, 2009
Fine-scale geographic variations of inflammatory bowel disease in France: correlation with socioeconomic and house equipment variables
Virginie Nerich, Elisabeth Monnet, Alain Weill, et al.
Inflammatory Bowel Diseases
|
March 15, 2006
Geographical variations of inflammatory bowel disease in France: a study based on national health insurance data
Virginie Nerich, Elisabeth Monnet, Arnaud Etienne, et al.
Page
of 1